wire - news in brief

« BACK

Medicine/Pharmacology



Results 1 - 50 of 1090.
1 2 3 4 5 ... 22 Next »

Medicine/Pharmacology - Physics/Materials Science
27.04.2017
Getting a Handle on Safety
Getting a Handle on Safety
Protons can accurately target and eliminate cancerous cells by erasing their genetic substance DNA. Doctors at the Centre for Proton Therapy at the Paul Scherrer Institute PSI use protons to treat patients with deep-seated tumours or ocular cancer.
Medicine/Pharmacology - Business/Economics
26.04.2017
Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma Now available in the UK, G
Business/Economics - Medicine/Pharmacology
25.04.2017
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued Net sales grew 2% (cc, -1
Medicine/Pharmacology - Life Sciences
24.04.2017
Novartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the range expected for people without MS   Approximately 60% of patients achieved NEDA-3 (no relapses, no MRI lesions and no disability progression combined) and 38% achieved NEDA-4 (NEDA-3 plus no brain shrinkage), further supporting findings from clinic
Medicine/Pharmacology - Life Sciences
24.04.2017
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada Novartis and Amgen to co-commercialize AMG 334
Medicine/Pharmacology - Life Sciences
21.04.2017
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases.
Medicine/Pharmacology
21.04.2017
EPFL non-profit iM4TB awarded $2.45m for anti-TB drug clinical trials
EPFL non-profit iM4TB awarded $2.45m for anti-TB drug clinical trials
The Bill & Melinda Gates foundation has awarded EPFL-based non-profit iM4TB $2.45 million to take their innovative anti-tuberculosis drug PBTZ169 into clinical trials.
Medicine/Pharmacology - Administration/Government
20.04.2017
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia NIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard immunosuppressive therapy   The historical complete response rate was 10% for untreated patients with SAA on immunosup
Medicine/Pharmacology - Life Sciences
19.04.2017
Action Required: Invasive Fungus Is Killing European Salamanders
The situation is alarming: The invasive Asian fungus has recently led to mass mortality of fire salamanders in the Netherlands, Belgium and Germany.
Medicine/Pharmacology - Life Sciences
19.04.2017
Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS? (ocrelizumab) in two types of multiple sclerosis
Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS? (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and
Medicine/Pharmacology - Life Sciences
18.04.2017
FDA grants Roche’s TECENTRIQ (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer
FDA grants Roche's TECENTRIQ (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder
Medicine/Pharmacology
18.04.2017
FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States
FDA approves Roche's Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat
Medicine/Pharmacology - Life Sciences
18.04.2017
Chaining up diarrhoea pathogens
Chaining up diarrhoea pathogens
Researchers have clarified how vaccinations can combat bacterial intestinal diseases: vaccine-induced antibodies in the intestine chain up pathogens as they grow in the intestine, which prevents disease and surprisingly also hinders the spread of antibiotic resistance. Vaccinations are known to protect against pathogens such as bacteria or viruses.
Medicine/Pharmacology - Life Sciences
18.04.2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)   R/r DLBCL, an aggressive cancer with limited options, is the second indication for CTL019 to receive Breakthrough Therapy designation   Advances in CTL019 result from collaboration with the University of Pennsylvania; regulatory submissions for r/r DLBCL are expected
Medicine/Pharmacology - Business/Economics
18.04.2017
Novartis expands development programs for NASH through clinical collaboration with Allergan
Phase IIb clinical trial to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive  form of non-alcoholic fatty liver disease   There are currently no ap
Medicine/Pharmacology - Life Sciences
18.04.2017
Synthetic Carbohydrates against Autoimmune Diseases
Researchers are developing an innovative approach for the treatment of a rare autoimmune disease of the peripheral nervous system, using a type of molecular sponge consisting of carbohydrates to remove pathogenic antibodies from the bloodstream. Developed to treat anti-MAG neuropathy, the approach also has potential applications for the treatment of other autoimmune diseases.
Medicine/Pharmacology - Administration/Government
17.04.2017
Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A
Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A Emicizumab prophylaxis reduced the number of bleeds in children with haemophilia A and inhibi
Medicine/Pharmacology - Life Sciences
10.04.2017
Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer
Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer Second Phase III head-to-head study that showed that Alecensa helped people with advanced ALK-positive non-small cell lung cancer (NSCLC) Results showed that people treated with Alecensa lived significantly longer without their disease progressing compared to crizotinib when given as initial (first-line) treatment Data will be submitted to global
Physics/Materials Science - Medicine/Pharmacology
06.04.2017
A better understanding of nanomaterials
A better understanding of nanomaterials
In the past six years, the National Research Programme "Opportunities and Risks of Nanomaterials" (NRP 64) intensively studied the development, use, behaviour and degradation of engineered nanomaterials, including their impact on humans and on the environment. Twenty-three research projects on biomedicine, the environment, energy, construction materials and food demonstrated the enormous potential of engineered nanoparticles for numerous applications in industry and medicine.
Medicine/Pharmacology - Business/Economics
06.04.2017
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
Novartis exercises an option to in-license ECF843, a recombinant form of human lubricin from Lubris LLC, for ophthalmic indications worldwide (outside Europe) Dry eye is an area with high unmet medic
Medicine/Pharmacology - Life Sciences
04.04.2017
Less Fear: how LSD Affects the Brain
Scientists at the University of Basel have shown that LSD reduces activity in the region of the brain related to the handling of negative emotions like fear. The results, published in the scientific journal Translational Psychiatry, could affect the treatment of mental illnesses such as depression or anxiety.
Medicine/Pharmacology - Life Sciences
03.04.2017
Novartis drug combination Tafinlar + Mekinist receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate in b
Medicine/Pharmacology - Life Sciences
03.04.2017
Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer
Phase III ALUR study supports the use of Roche's Alecensa for people with advanced ALK-positive lung cancer Results from the global, phase III ALUR trial showed that Alecensa significantly improved progression-free survival (PFS) in people with advanced ALK-positive non-small cell lung cancer (NSCLC) who had progressed following platinum-based chemotherapy and crizotinib, compared with chemotherapy Roche today announced that the phase III ALUR s
Medicine/Pharmacology
30.03.2017
Kidney Transplants: White Blood Cells Control Virus Replication
Kidney Transplants: White Blood Cells Control Virus Replication
Certain white blood cells play an important role in bringing a harmful virus under control after kidney transplantations. The results of a research group at the Department of Biomedicine at the University of Basel and University Hospital Basel could contribute to improving control of immunosuppression, avoiding transplant rejection and developing relevant vaccines.
Medicine/Pharmacology - Life Sciences
29.03.2017
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T'cells Novartis made an early commitment to the emer
Medicine/Pharmacology - Life Sciences
29.03.2017
FDA approves Roche‘s OCREVUS’ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis
FDA approves Roche‘s OCREVUS' (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis First and only approved disease-modifying therapy for primary progressive form of m
Medicine/Pharmacology - Business/Economics
26.03.2017
Medicine/Pharmacology
23.03.2017
Alcon receives US FDA approval for new AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
Alcon receives US FDA approval for new AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction The unique optical desig
Medicine/Pharmacology
22.03.2017
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure   Novartis remains committed to improving and extending the lives of patients with cardiovascular disease and will continue to invest in ways to improve their outcomes Basel, March 22, 2017 - Novartis today announced results from the global Phase III RELAX-AHF-2 study investigating the efficacy, safety and tolerability of RLX030 (serelaxin) in patients with acute heart failure (AHF).
Medicine/Pharmacology - Administration/Government
21.03.2017
Novartis’ Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment   Patients with longer disease duration before treatment with Co
Medicine/Pharmacology - Administration/Government
18.03.2017
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs.
Life Sciences - Medicine/Pharmacology
17.03.2017
Cut the long story short - and stitch it back together
Cut the long story short - and stitch it back together
Media releases, information for representatives of the media Media Relations (E) A species of unicellular ciliate has found a special trick to make use of the cellular machinery in seemingly impossible ways.
Medicine/Pharmacology - Computer Science/Telecom
14.03.2017
Is Reliable Artificial Intelligence Possible?
Is Reliable Artificial Intelligence Possible?
In the quest for reliable artificial intelligence, EPFL scientist Marcel Salathé argues that AI technology should be openly available.
Medicine/Pharmacology - Physics/Materials Science
14.03.2017
Rays of hope for patients
Rays of hope for patients
Tumours of the eye are rare. Yet for those affected, they mean a stroke of fate that involves not only the loss of vision but often the whole eye as well.
Medicine/Pharmacology
13.03.2017
Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines.
Medicine/Pharmacology - Life Sciences
13.03.2017
Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor Approved based on a first-line P
Medicine/Pharmacology - Life Sciences
13.03.2017
Joint Efforts Towards Treating Paralysis
EPFL scientists Stéphanie Lacour and Grégoire Courtine report on the status of their research and share their vision about the future of wearable neuroprosthetics at this year's edition of South by South West in Austin, Texas, on March 12 th .
Medicine/Pharmacology
09.03.2017
People who Trust Their Doctor Tend to Feel Better
Confidence in doctors, therapists and nursing staff leads to an improvement in subjectively perceived complaints, satisfaction and quality of life in patients. This is the conclusion of a meta-analysis by psychologists at the University of Basel, published in the journal PLOS ONE. Trust in doctors, therapists and nursing staff is a key requirement when treating patients, and is already laid down as a principle in the ethical guidelines and professional codes of each clinical field.
Medicine/Pharmacology - Life Sciences
06.03.2017
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira * Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis Study reinforces strength of Sandoz pipeline and its key role in the broader Novartis immunology portfolio Holzkirchen, 6 March 2017 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today presented data for its proposed biosimilar adalimumab (GP2017).
Medicine/Pharmacology
06.03.2017
Novartis’ Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
New analysis shows 94% of patients on Cosentyx regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment   Cosentyx has shown superior and sustained results versus both Stelara and Enbrel, delivering long-lasting clear or almost clear skin (PASI 90 to 100) ,   Cosentyx has treated 80,000 patients worldwide to date and is the only IL-17A inhibitor approved in psoriasis, psoriatic arthritis and ankylo
Medicine/Pharmacology - Administration/Government
02.03.2017
Roche’s Perjeta regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin and chemotherapy
Phase III APHINITY study shows Roche's Perjeta regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin and chemotherapy
Medicine/Pharmacology - Administration/Government
01.03.2017
Better health services for the chronically ill
Better health services for the chronically ill
The SNSF is launching the National Research Programme ‘Smarter Health Care'. 29 research teams will be looking for ways of providing better and more cost-efficient health services for people with chronic diseases.
Life Sciences - Medicine/Pharmacology
28.02.2017
Stem cells derived neuronal networks grown on a chip as an alternative to animal testing
Stem cells derived neuronal networks grown on a chip as an alternative to animal testing
Media releases, information for representatives of the media Media Relations (E) Scientists at the Institute for Infectious Diseases, University of Bern have developed an in vitro stem cell-based bio
Medicine/Pharmacology - Life Sciences
24.02.2017
Novartis receives positive CHMP opinion for Tafinlar + Mekinist in BRAF-positive non-small cell lung cancer (NSCLC) patients
If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients with B
Medicine/Pharmacology - Life Sciences
23.02.2017
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
Priority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs.
Medicine/Pharmacology - Mechanical Engineering/Mechanics
21.02.2017
Innovation cannot be taught; it must be learned
Innovation cannot be taught; it must be learned
ETH President Lino Guzzella welcomed Alexander van der Bellen to the University on Friday, where the Austrian President was shown how ETH is encouraging innovation.
Environment/Sustainable Development - Medicine/Pharmacology
21.02.2017
Selenium deficiency promoted by climate change
Selenium deficiency promoted by climate change
As a result of climate change, concentrations of the trace element selenium in soils are likely to decrease.
Medicine/Pharmacology - Life Sciences
18.02.2017
Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Phase II study supports potential for Roche's TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma Proof of concept study in first line mRCC (a type of kidney cancer) shows that TECENTRIQ and Avastin can be combined with a manageable safety profile Study results also showed encouraging efficacy compared to sunitinib in those people whose disease expressed the PD-L1 (programmed de
Computer Science/Telecom - Medicine/Pharmacology
06.02.2017
Switzerland Launches a National Center for Data Science
Switzerland Launches a National Center for Data Science
Switzerland is creating a National Center for Data Science to foster innovation in data science, multidisciplinary research and open science.
Medicine/Pharmacology - Life Sciences
31.01.2017
Novartis drug Votubia receives EU approval to treat refractory partial-onset seizures in patients with TSC
Votubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC)   Approval addresses unmet need as up
1 2 3 4 5 ... 22 Next »